UB Paderborn / Katalog / Suche / in CDI

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

The lancet oncology, 2019-08, Vol.20 (8), p.1109-1123

2019

Link zum Volltext

Verfügbarkeit prüfen

Health-related quality of life as an endpoint in oncology phase I trials: a systematic review

BMC cancer, 2019-04, Vol.19 (1), p.361-361, Article 361

2019

Link zum Volltext

Verfügbarkeit prüfen

Membrane-bound exosomal HSP70 as a biomarker for detection and monitoring of malignant solid tumours: a pilot study

Pilot and feasibility studies, 2020-03, Vol.6 (1), p.35-35, Article 35

2020

Link zum Volltext

Verfügbarkeit prüfen

EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib

PloS one, 2018-09, Vol.13 (9), p.e0204117-e0204117

2018

Link zum Volltext

Verfügbarkeit prüfen

ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment

Journal for immunotherapy of cancer, 2023-09, Vol.11 (9), p.e007552

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study

The lancet oncology, 2019-01, Vol.20 (1), p.120-133

2019

Link zum Volltext

Verfügbarkeit prüfen

Socio-demographic inequalities in stage at diagnosis of lung cancer: A French population-based study

Cancer epidemiology, 2024-04, Vol.89, p.102522-102522, Article 102522

2024

Link zum Volltext

Verfügbarkeit prüfen

Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group

European journal of cancer (1990), 2017-09, Vol.83, p.125-131

2017

Link zum Volltext

Verfügbarkeit prüfen

Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial

The lancet oncology, 2022-08, Vol.23 (8), p.1044-1054

2022

Link zum Volltext

Verfügbarkeit prüfen

Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE

European journal of cancer (1990), 2021-10, Vol.156, p.12-23

2021

Link zum Volltext

Verfügbarkeit prüfen

A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification

European journal of cancer (1990), 2017-12, Vol.87, p.131-139

2017

Link zum Volltext

Verfügbarkeit prüfen

PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer

European journal of cancer (1990), 2017-11, Vol.86, p.28-36

2017

Link zum Volltext

Verfügbarkeit prüfen

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort

Targeted oncology, 2021-07, Vol.16 (4), p.435-446

2021

Link zum Volltext

Verfügbarkeit prüfen

Low Cross-Reactivity Between Cisplatin and Other Platinum Salts

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2019-07, Vol.7 (6), p.1894-1900

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer

Cancer chemotherapy and pharmacology, 2018-12, Vol.82 (6), p.979-986

2018

Link zum Volltext

Verfügbarkeit prüfen

Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program

BMC cancer, 2013-02, Vol.13 (1), p.64-64, Article 64

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors

BMC cancer, 2013-04, Vol.13 (1), p.172-172, Article 172

2013

Link zum Volltext

Verfügbarkeit prüfen

Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study

Targeted oncology, 2021-07, Vol.16 (4), p.485-492

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours

BMC cancer, 2013-10, Vol.13 (1), p.460-460, Article 460

2013

Link zum Volltext

Verfügbarkeit prüfen

Management of Cancer Cachexia and Guidelines Implementation in a Comprehensive Cancer Center: A Physician-Led Cancer Nutrition Program Adapted to the Practices of a Country

Journal of pain and symptom management, 2017-09, Vol.54 (3), p.387-393.e3

2017

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

Health-related quality of life as an endpoint in oncology phase I trials: a systematic review

Membrane-bound exosomal HSP70 as a biomarker for detection and monitoring of malignant solid tumours: a pilot study

Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)

EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib

ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment

Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network

Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study

Socio-demographic inequalities in stage at diagnosis of lung cancer: A French population-based study

Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group

Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial

Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE

A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification

PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer

TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort

Low Cross-Reactivity Between Cisplatin and Other Platinum Salts

Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer

Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program

Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors

Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study

Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours

Management of Cancer Cachexia and Guidelines Implementation in a Comprehensive Cancer Center: A Physician-Led Cancer Nutrition Program Adapted to the Practices of a Country

Aktive Filter

Suchergebnisse filtern